Evidence supporting the use of biomarkers in cerebrospinal fluid (CSF) and plasma continues to accumulate, and these markers may help predict which patients will develop Alzheimer’s disease (AD), an expert panel says.
The panel met in Geneva in 2019 to review recent evidence and provide an up-to-date analysis of the use of fluid biomarkers in AD. The output was presented at AAIC 2020 by Dr Antoine Leuzy of Lund University, Sweden.
Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.